Skip to main content

Advertisement

SpringerLink
Log in

Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update

  • Special Report
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Weinstein RS (2011) Glucocorticoid-induced bone disease. N Engl J Med 365:62–70

    Article  CAS  PubMed  Google Scholar 

  2. Van Staa TP, Leukens HGM, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787

    Article  PubMed  Google Scholar 

  3. LoCascio V, Bonucci E, Imbimbo B, Ballanti P, Adami S, Milani S, Tartarotti D, DellaRocca C (1990) Bone loss in response to long-term glucocorticoid therapy. Bone Miner 8:39–51

    Article  CAS  PubMed  Google Scholar 

  4. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48:3224–3229

    Article  PubMed  Google Scholar 

  5. American College of Rheumatology Task Force on Osteoporosis Guidelines (1996) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 39:1791–1801

    Article  Google Scholar 

  6. Adachi JD, Olszynski WP, Hanley DA, Hodsman AB, Kendler DL, Siminoski KG, Brown J, Cowden EA, Goltzman D, Ioannidis G, Josse RG, Ste-Marie LG, Tenenhouse AM, Davison KS, Blocka KL, Pollock AP, Sibley J (2000) Management of corticosteroid-induced osteoporosis. Sem Arthritis Rheum 29:228–251

    Article  CAS  Google Scholar 

  7. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis 2001 update. Arthritis Rheum 44:1496–1503

    Article  Google Scholar 

  8. Royal College of Physicians (2002) Glucocorticoid-induced osteoporosis: Guidelines on Prevention and Treatment. Bone and Tooth Society of Great Britain. National Osteoporosis Society and Royal College of Physicians, London

    Google Scholar 

  9. Nawata H, Soen S, Takayanagi R, Tanaka I, Takaoka K, Fukunaga M, Matsumoto T, Suzuki Y, Tanaka H, Fujiwara S, Miki T, Sagawa A, Nishizawa Y, Seino Y (2005) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 23:105–109

    Article  PubMed  Google Scholar 

  10. Kanis JA (2007) On behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health care level. WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield

  11. Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028–2039

    Article  CAS  PubMed  Google Scholar 

  12. Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60:3346–3355

    Article  CAS  PubMed  Google Scholar 

  13. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, Curtis JR, Furst DE, McMahon M, Patkar NM, Volkmann E, Saag KG (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 62:1515–1526

    Article  Google Scholar 

  14. Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgström F, Cooper C, Diez Perez A, Eastell R, Hofbauer LC, Kanis JA, Langdahl BL, Lesnyak O, Lorenc R, McCloskey E, Messina OD, Napoli N, Obermayer-Pietsch B, Ralston SH, Sambrook PN et al (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 23:2257–2276

    Article  CAS  PubMed  Google Scholar 

  15. Kirigaya D, Nakayama T, Ishizaki T, Ikeda S, Satoh T (2011) Management and treatment of osteoporosis in patients receiving long-term glucocorticoid treatment: current status of adherence to clinical guidelines and related factors. Intern Med 50:2793–2800

    Article  CAS  PubMed  Google Scholar 

  16. Guzman-Clark JR, Fang MA, Sehl ME, Traylor L, Hahn TJ (2007) Barriers in the management of glucocorticoid-induced osteoporosis. Arthritis Rheum 57:140–146

    Article  PubMed  Google Scholar 

  17. Compston J (2011) Clinical question: what is the best approach to managing glucocorticoid-induced osteoporosis. Clin Endocrinol (Oxf) 74:547–550

    Article  CAS  Google Scholar 

  18. The Ad Hoc Committee to develop Guidelines for Prevention and Treatment of Osteoporosis (The Japanese Society for Bone and Mineral Research/Japan Osteoporosis Society Collaborative Initiative.) (2011) Guidelines for Prevention and Treatment of Osteoporosis, 2011th edn. Life Science, Tokyo

    Google Scholar 

  19. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292–299

    Article  CAS  PubMed  Google Scholar 

  20. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA et al (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202–211

    Article  CAS  PubMed  Google Scholar 

  21. de Nijs RN, Jacobs JW, Lems WF, Laan RF, Algra A, Huisman AM, Buskens E, de Laet CE, Oostveen AC, Geusens PP, Bruyn GA, Dijkmans BA, Bijlsma JW, STOP Investigators (2006) Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 355:675–684

    Article  PubMed  Google Scholar 

  22. Stoch SA, Saag KG, Greenwald M, Sebba AI, Cohen S, Verbruggen N, Giezek H, West J, Schnitzer TJ (2009) Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol 36:1705–1714

    Article  CAS  PubMed  Google Scholar 

  23. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA (1999) Risedronate therapy prevents corticosteroid-induced bone loss: a twelve month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42:2309–2318

    Article  CAS  PubMed  Google Scholar 

  24. Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15:1006–1013

    Article  CAS  PubMed  Google Scholar 

  25. Reid DM, Adami S, Devogelaer JP, Chines AA (2001) Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 69:242–247

    Article  CAS  PubMed  Google Scholar 

  26. Eastell R, Devogelaer JP, Peel NF, Chines AA, Bax DE, Sacco-Gibson N, Nagant de Deuxchaisnes C, Russell RG (2000) Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 11:331–337

    Article  CAS  PubMed  Google Scholar 

  27. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA (1997) Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337:382–387

    Article  CAS  PubMed  Google Scholar 

  28. Roux C, Oriente P, Laan R, Hughes RA, Ittner J, Goemaere S, Di Munno O, Pouillès JM, Horlait S, Cortet B (1998) Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. J Clin Endocrinol Metab 83:1128–1133

    Article  CAS  PubMed  Google Scholar 

  29. Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F (2003) Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from long-term comparative study. Osteoporos Int 14:801–807

    Article  CAS  PubMed  Google Scholar 

  30. Ringe JD, Dorst A, Faber H, Ibach K, Preuss J (2003) Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. Rheumatology 42:743–749

    Article  CAS  PubMed  Google Scholar 

  31. Hakala M, Kröger H, Valleala H, Hienonen-Kempas T, Lehtonen-Veromaa M, Heikkinen J, Tuomiranta T, Hannonen P, Paimela L, ONCE trial group (2012) Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind. Placebo-controlled trial. Scand J Rheumatol 41:260–266

    Article  CAS  PubMed  Google Scholar 

  32. Fahrleitner-Pammer A, Piswanger-Soelkner JC, Pieber TR, Obermayer-Pietsch BM, Pilz S, Dimai HP, Prenner G, Tscheliessnigg KH, Hauge E, Portugaller RH, Dobnig H (2009) Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial. J Bone Miner Res 24:1335–1344

    Article  CAS  PubMed  Google Scholar 

  33. Reginster JY, Kuntz D, Verdickt W, Wouters M, Guillevin L, Menkès CJ, Nielsen K (1999) Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int 9:75–81

    Article  CAS  PubMed  Google Scholar 

  34. Ringe JD, Cöster A, Meng T, Schacht E, Umbach R (1999) Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium. Calcif Tissue Int 65:337–340

    Article  CAS  PubMed  Google Scholar 

  35. Sambrook PN, Kotowicz M, Nash P, Styles CB, Naganathan V, Henderson-Briffa KN, Eisman JA, Nicholson GC (2003) Prevention and treatment of glucocorticoid-induced osteoporosis.: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 18:919–924

    Article  CAS  PubMed  Google Scholar 

  36. Amin S, Lavalley MP, Simms RW, Felson DT (2002) The comparative efficacy of drug therpies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 17:1512–1526

    Article  CAS  PubMed  Google Scholar 

  37. de Nijs RN, Jacobs JW, Algra A, Lems WF, Bijlsma JW (2004) Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int 15:589–602

    Article  PubMed  Google Scholar 

  38. Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, Krohn K, See K, Warner MR (2009) Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int 20:2095–2104

    Article  CAS  PubMed  Google Scholar 

  39. Devogelaer JP, Adler RA, Recknor C, See K, Warner MR, Wong M, Krohn K (2010) Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J Rheumatol 37:141–148

    Article  CAS  PubMed  Google Scholar 

  40. Karras D, Stoykov I, Lems WF, Langdahl BL, Ljunggren Ö, Barrett A, Walsh JB, Fahrleitner-Pammer A, Rajzbaum G, Jakob F, Marin F (2012) Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study. J Rheumatol 39:600–609

    Article  CAS  PubMed  Google Scholar 

  41. Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ (2000) Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:2129–2134

    CAS  PubMed  Google Scholar 

  42. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479–1491

    Article  PubMed  Google Scholar 

  43. Urade M, Tanaka N, Furusawa K, Shimada J, Shibata T, Kirita T, Yamamoto T, Ikebe T, Kitagawa Y, Fukuta J (2011) Nationwide survey for bisphosphonate-related osteonecrosis of the jaws in Japan. J Oral Maxillofac Surg 69:e364–e371

    Article  PubMed  Google Scholar 

  44. Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Toyosawa S, Nagata T, Urade M (2010) Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and mineral Research, Japan Osteoporosis Society, Japanese Society for Oral and Maxillofacial Radiology and Japanese Society of Oral and Maxillofacila Surgeons. J Bone Miner Metab 28:365–383

    Article  CAS  PubMed  Google Scholar 

  45. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267–2294

    Article  PubMed  Google Scholar 

  46. Schilcher J, Michaëlsson K, Aspenberg P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364:1728–1737

    Article  CAS  PubMed  Google Scholar 

  47. Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1–23

    Article  PubMed  Google Scholar 

  48. Levy S, Fayez I, Taguchi N, Han JY, Aiello J, Matsui D, Moretti M, Koren G, Ito S (2009) Pregnancy outcome following in utero exposure to bisphosphonates. Bone 44:428–430

    Article  CAS  PubMed  Google Scholar 

  49. Ornoy A, Wajnberg R, Diav-Citrin O (2006) The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. Reprod Toxicol 22:578–579

    Article  CAS  PubMed  Google Scholar 

  50. Chan B, Zacharin M (2006) Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases. J Clin Endocrinol Metab 91:2017–2020

    Article  CAS  PubMed  Google Scholar 

  51. Munns CF, Rauch F, Ward L, Glorieux FH (2004) Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res 19:1742–1745

    Article  PubMed  Google Scholar 

  52. Siminoski K, Fitzgerald AA, Flesch G, Gross MS (2000) Intravenous pamidronate for treatment of reflex sympathetic dystrophy during breast feeding. J Bone Miner Res 15:2052–2055

    Article  CAS  PubMed  Google Scholar 

  53. MaNicholl DM, Heaney LG (2010) The safety of bisphosphonate use in premenopausal women on corticosteroids. Curr Drug Saf 5:182–187

    Article  Google Scholar 

Download references

Conflict of interest

Y. S. has received research funding from Mitsubishi-Tanabe, Eisai, AbbVie, Pfeizer, Ono, Toyama Chemical, Japan Blood Products Organization, Takeda, Chugai, and Astellas, and has received honoraria or fees for promotional materials from Pfizer, Takeda, Eisai, and Mitsubishi-Tanabe. S. S. has received consulting fees, speaking fees, and/or honoraria from Asahi Kasei Pharma, Astellas, Chugai, Daiichi-Sankyo Eizai, Eli Lilly Japan, MSD, Ono, Pfizer, Takeda, Teijin Pharma. S. F. has received speaking fees, and/or honoraria from Daiichi-Sankyo and Ono. H. N. has received speaking fees from Abbvie, Chugai, Astellas, Takeda, Pfizer, Janssen, Eisai, Daiichi-Sankyo., Teijin, Lilly, Ono, and Asahikasei. I. T. has received speaking fees, and/or honoraria from Chugai, Astellas, Takeda, Mitsubishi-Tanabe, Pfizer, Eisai, Daiichi-Sankyo, Eizai, Asahikasei, Teijin, Eli Lilly Japan , Taisho-Toyama, Ono and MSD. K. O. has received consulting fees, speaking fees, and/or honoraria from Chugai, Eli Lilly Japan, MSD, Pfizer, Teijin Pharma. R. T. has received speaking fees from Astellas, Daiichi-Sankyo and Eli Lilly. T. M. has received speaking fees, and/or research funding from Chugai, Takeda, Pfizer, Eisai, Daiichi-Sankyo, Taisho-Toyama, Teijin Farma, MSD, Ono and Elilly Japan. Y. T. has received consulting fees, speaking fees, and/or honoraria from Abbvie, Chugai, Astellas, Takeda, Santen, Mitsubishi-Tanabe, Pfizer, Janssen, Eisai, Daiichi-Sankyo, UCB, GlaxoSmithKline, Bristol-Myers.

Author information

Authors and Affiliations

  1. Committee for the Revision of Guidelines on the Management and Treatment of Glucocorticoid-Induced Osteoporosis of the Japanese Society for Bone and Mineral Research, Kobe, Japan

    Yasuo Suzuki, Hajime Nawata, Satoshi Soen, Saeko Fujiwara, Hisanori Nakayama, Ikuko Tanaka, Keiichi Ozono, Akira Sagawa, Ryoichi Takayanagi, Hiroyuki Tanaka, Takami Miki & Yoshiya Tanaka

  2. Working Group for the Revision of Guidelines on the Management and Treatment of Glucocorticoid-Induced Osteoporosis of the Japanese Society for Bone and Mineral Research, Kobe, Japan

    Yasuo Suzuki, Satoshi Soen, Saeko Fujiwara, Hisanori Nakayama, Ikuko Tanaka, Naomi Masunari & Yoshiya Tanaka

  3. Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan

    Yasuo Suzuki

  4. Department of Medicine, Seiwakai Muta Hospital, Fukuoka, Japan

    Hajime Nawata

  5. Department of Orthopaedic Surgery and Rheumatology, Nara Hospital, Kinki University School of Medicine, Ikoma, Japan

    Satoshi Soen

  6. Health Management and Promotion Center, Hiroshima Atomic Bomb Casualty Council, Hiroshima, Japan

    Saeko Fujiwara

  7. Soshigayaokura Clinic, Tokyo, Japan

    Hisanori Nakayama

  8. Nagoya Rheumatology Clinic, Nagoya, Japan

    Ikuko Tanaka

  9. Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan

    Keiichi Ozono

  10. Sagawa-Akira Rheumatology Clinic, Sapporo, Japan

    Akira Sagawa

  11. Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

    Ryoichi Takayanagi

  12. Department of Pediatrics, Okayama Saiseikai General Hospital, Okayama, Japan

    Hiroyuki Tanaka

  13. Department of Geriatrics and Neurology, Osaka City University Graduate School of Medicine, Osaka, Japan

    Takami Miki

  14. Department of Liberal Arts and Basic Science, The Japanese Red Cross Kyushu International College of Nursing, Munakata, Japan

    Naomi Masunari

  15. The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan

    Yoshiya Tanaka

Authors
  1. Yasuo Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hajime Nawata
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Satoshi Soen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Saeko Fujiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hisanori Nakayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ikuko Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Keiichi Ozono
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Akira Sagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ryoichi Takayanagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hiroyuki Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Takami Miki
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Naomi Masunari
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yoshiya Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yasuo Suzuki.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Suzuki, Y., Nawata, H., Soen, S. et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab 32, 337–350 (2014). https://doi.org/10.1007/s00774-014-0586-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-014-0586-6

Keywords

Search

Navigation